Oral Progestin Regimen for Women with Prior Endometrial Hyperplasia
For a woman with a prior history of endometrial hyperplasia requiring hormone therapy, medroxyprogesterone acetate (MPA) 10 mg daily for 12-14 days per month is the recommended oral progestin regimen, or alternatively, micronized progesterone 200 mg daily for 12-14 days per month. 1
Recommended Oral Progestin Options
The following oral progestins have demonstrated endometrial protection in women with prior hyperplasia 1:
First-line choices:
- Medroxyprogesterone acetate (MPA): 10 mg daily for 12-14 days per month (cyclic) OR 2.5 mg daily (continuous)
- Micronized progesterone: 200 mg daily for 12-14 days per month (cyclic) OR 100 mg daily (continuous)
Alternative options:
- Norethindrone acetate: 5 mg for 10-12 days per month
- Dydrogesterone: 10 mg daily for 12-14 days per month 2
Critical Considerations for Prior Hyperplasia
The cyclic regimen (12-14 days per month) is strongly preferred over continuous daily dosing when there is a history of hyperplasia, as it provides more robust endometrial protection and allows for withdrawal bleeding that can signal endometrial changes 1. The continuous combined approach using lower doses (MPA 2.5 mg daily) may be considered if the patient cannot tolerate cyclic bleeding, but requires closer monitoring.
Monitoring Requirements
Given her prior hyperplasia history, this patient requires:
- Endometrial surveillance with biopsy if any abnormal bleeding occurs 3
- Low threshold for endometrial sampling with unexpected bleeding patterns 1
- Annual clinical review focusing on compliance 4
Alternative: Levonorgestrel-IUD
If oral progestins are not tolerated or compliance is a concern, the levonorgestrel-releasing intrauterine device (LNG-IUD) provides superior endometrial protection compared to oral progestins, with regression rates of 92% vs 66% for complex hyperplasia 5, 6. The LNG-IUD achieves local endometrial effects with minimal systemic absorption 1.
Important Caveats
Avoid long-cycle therapy (progestin every 3 months) in women with prior hyperplasia, as this has not been adequately validated for endometrial protection 1. The standard 12-14 day monthly exposure is essential for adequate endometrial transformation and protection against recurrent hyperplasia.
Micronized progesterone may have advantages over synthetic progestins regarding cardiovascular and breast cancer risk 2, making it an excellent first choice if the patient has additional risk factors. However, MPA has the strongest evidence base for endometrial protection specifically 1.
If she develops breakthrough bleeding or persistent irregular bleeding on any regimen, immediate endometrial sampling is mandatory to exclude recurrent hyperplasia or progression 3, 1.